Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.

Before targeted therapies like trastuzumab, patients with HER2-positive lung cancer had limited options apart from standard chemotherapy, with generally poor outcomes and greater side effects.

HER2 is a protein that can cause a more aggressive form of breast cancer. What to know if your doctor tells you that you have "HER2-positive" breast cancer.

Medically reviewed by Lindsay Cook, PharmD If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and ...

HER2-positive breast cancer is a fast-growing type. Learn about its symptoms, causes, treatment, and prevention options. Early detection and targeted therapy can lead to a cure.

With ever-growing treatment options, clinical care access and a new focus on integrative strategies, cancer centers are constantly upgrading their services and options for patients. Becker’s asked ...

Published in npj Breast Cancer, the study combined the HER2-targeting dendritic cell vaccines with standard chemotherapy, demonstrating both safety and positive response rates.

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC ...

An AI-based EGFR biomarker tool could preclude the need for a rapid PCR test in nearly half of advanced lung adenocarcinoma cases, a study has suggested.

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive metastatic breast cancer.

A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 ...

Arturo Loaiza-Bonilla, MD, MSEd, systemwide chief of hematology and oncology at St. Lukes University Health Network and ...